| |
De-risk your biological product supply with a seamless technology transfer. With more than 50 new product introductions in the last 12 months across biological modalities, Lonza is an experienced partner for clinical and commercial biological product manufacturing in liquid/lyo vials and prefilled syringes. Discover how.
|
|
Today’s Big NewsMay 15, 2024 |
| By James Waldron BioMarin had already announced plans to cut its pipeline in half, but now the company has confirmed that 170 employees are also leaving the building as part of the R&D restructure. |
|
|
|
By Fraiser Kansteiner Eisai has laid out an ambitious goal to hit 56.5 billion yen (roughly $364 million) in global Leqembi sales for the 2024 fiscal year, which wraps up next March. Eisai banked its estimate on the fact that the company and its partner Biogen have steadily improved Alzheimer’s disease diagnosis and treatment pathways over the past year. |
By James Waldron In another tough day for biotech employees, Bolt Biotherapeutics and Tenaya Therapeutics both outlined plans to significantly scale back their workforces. |
By Conor Hale Once known for tackling everything from smart contact lenses to surgical robots, Verily has pulled back from its many projects to focus on a more centralized goal. |
|
Wednesday, May 22, 2024 | 10am ET / 7am PT In this webinar, we'll explore how emerging technologies aid Medical Affairs teams in understanding their research's online influence and reaching the right audiences. Topics include analyzing audience engagement, identifying influential opinion leaders, monitoring real-world conversations, and discovering emerging researchers. Register now.
|
|
By Max Bayer Immunology and inflammation-focused drug development has become scorching hot business. This time, Uniquity Bio unveiled with $300 million from Blackstone. |
By Andrea Park Naming a new trial represents a significant marketing opportunity for drug and device makers well before their products ever hit shelves, especially because study monikers, unlike drug names, aren’t subject to regulatory oversight. |
By Angus Liu Novo Holdings has made another investment in biopharma manufacturing, as its key portfolio company, Novo Nordisk, looks to bolster production for its sought-after diabetes and weight-loss drugs. |
By Conor Hale The separate self-collection offerings from BD and Roche still need to be used in a healthcare setting—they have not received agency green lights for solo, at-home use. |
By Ben Adams Merck’s cancer drug giant Keytruda has helped the Big Pharma top how oncologists see cancer drugmakers, but no one company is dominating the field. |
By Annalee Armstrong Vaxxinity, which filed to delist from the Nasdaq last month, is choosing radical transparency about the “abusive relationship” that has defined the immunotherapy medicine company’s three-year stint as a public company. |
By Nick Paul Taylor Thirty seconds. That’s the sweet spot for pharma ads on connected TV. Ad tech company Innovid made the discovery in an analysis of the almost 380 billion video advertising impressions served on its platform last year. |
By Kevin Dunleavy On Wednesday—amid largely positive news for Merck KGaA overall—the company reported a 17% decline in sales for its CDMO unit, blaming (PDF) “unfavorable project phasing” and a streamlining of the supply chain of one of its customers. |
By Andrea Park The next Mindy Kaling project? Advocating for people with plaque psoriasis. |
Fierce podcastsDon’t miss an episode |
| This week’s episode of “The Top Line,” kicks off a series diving into the latest advancements in cell and gene therapy manufacturing. |
|
|---|
|
|
|
Wednesday, June 5, 2024 | 2pm ET / 11am PT Delayed diagnosis of autoimmune diseases is common due to subjective symptoms, lack of definitive testing, and gender bias. This can cause worsening symptoms and disease progression, while simultaneously leading to missed research opportunities and reduced revenue for pharma. Join us to learn about key advancements in RWD for helping address these issues. Register now.
|
|
| WhitepaperPrecision collection of cell therapy source material doesn’t happen by chance. Our new whitepaper illuminates the science and strategies for successful apheresis. Sponsored by: Comprehensive Cell Solutions |
| WhitepaperLearn how Specifica’s in vitro antibody discovery platform can deliver better antibodies than traditional immunization approaches. Sponsored by: Specifica, a Q2 Solutions company |
| WhitepaperThis paper defines “digital companions” in biopharma, explores their value from the patient & company perspectives, & outlines a process for successfully fielding a new digital companion. Presented by: Blue Matter, strategic consultants in the life sciences |
| WhitepaperExplore the complex considerations of vaccine development for influenza and COVID-19, including the challenges posed by viral evolution and the importance of ongoing research in this paper by vaccine expert, Dr. Lisa Kierstead. Sponsored by: PPD®️ Laboratory Services |
| eBookTo make every rare disease trial count, we design patient-centric, relevant strategies for sponsors and caregivers to produce impactful results every time. Sponsored by: Emmes Company |
| WhitepaperDiscover the secrets behind successful patient engagement Sponsored by: ProofPilot |
| WhitepaperAntibody biomarkers are redefining precision medicine, from diagnosing diseases earlier to stratifying patients – download your FREE white paper today! Sponsored by: Sengenics Corporation LLC |
| WhitepaperThe use of prefilled syringes to administer biotherapeutics is beginning to gain traction because they offer a range of stability, efficacy, and patient safety benefits. Download this white paper to learn how Lonza has developed a novel workflow to ensure confidence regarding functionality in PFS and autoinjectors. Presented by Lonza |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
